Select your country

Africa
Asia
Europe
Latin America
North America
Oceania

Immunology

Resolute drive powers what we do. Purposeful discovery is our promise. We will never give up our search for ways to improve the lives of people living with chronic progressive diseases.


Dedicated to our goal of delivering new solutions

This drive and discovery has shaped our legacy in immunology and will pave the way for delivering new solutions to the people we serve.

We are growing a robust pipeline with a range of new therapies that have the potential to alter treatment paradigms for such chronic conditions as multiple sclerosis, systemic lupus erythematosus, osteoarthritis and rheumatoid arthritis.

We are discovering new ways to optimize outcomes for a range of chronic progressive diseases by pursuing novel pathways that modulate the immune system in more targeted manners than traditional immunosuppressants.

For immune disorders, we develop approaches that target the innate and adaptive components of the immune system. This includes inhibiting the inappropriate immune activation that contributes to the disorder, as well as enhancing immune tolerance, which trains the body not to react to triggers.

For the treatment of forms of arthritis, our investigational therapies feature approaches that may facilitate cartilage repair homeostasis (a balance of re-growing cartilage and stopping cartilage from breaking down).

To deliver best in class therapies to patients, we are combining our significant internal scientific expertise with strategic external partnerships.

Browse the programs in our pipeline to see what we’re currently working on by phase, therapeutic area, and compound type. You can also see what we’ve discovered in-house versus those assets we’re partnering on with other giants in our industry. Learn more      

Our network of immunology alliances

Pfizer Inc. and the Broad Institute

Pfizer Inc. and the Broad Institute

This research agreement aims to identify biomarkers relevant to future therapies in the area of Systemic Lupus Erythematosus and Lupus Nephritis.

Institute of Experimental Neurology (INSPE), part of San Raffaele University and Research

Institute of Experimental Neurology (INSPE), part of San Raffaele University and Research

Since 2004, Merck KGaA, Darmstadt, Germany, and INSPE have been working together to develop pre-clinical and clinical research projects in the field of neurodegenerative diseases. The research is focusing on developing innovative therapies against serious and disabling neurological diseases affecting young adults in particular, such as multiple sclerosis. 

Avillion

Avillion

In a collaboration model that is recently emerging in the biopharma industry, Avillion, which is amongst the pioneers of such models, will be responsible for developing anti IL-17 A/F Nanobody® from Phase II through Phase III.

Nordic Bioscience

Nordic Bioscience

Under the terms of the agreement, Nordic Bioscience will provide clinical development services in a shared risk model for our investigational drug sprifermin (recombinant human FGF-18) in osteoarthritis of the knee. We retain full responsibility for the development and commercialization of the investigational drug.    

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement